Psych Capital Plc Logo

Psych Capital Plc

A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.

PSY | IL

Overview

Corporate Details

ISIN(s):
GB00BL6CJQ54
LEI:
213800WXCQ1C6GPLHH68
Country:
United Kingdom
Address:
17 HANOVER SQUARE, W1S 1BN LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shortwave Life Sciences Plc, formerly Psych Capital Plc, is a life sciences company focused on developing innovative treatments for mental health conditions. The company has transitioned from its prior role as an investment and media firm to a dedicated drug development entity following its acquisition of Short Wave Pharma. Its primary clinical program focuses on advancing psilocybin as a potential breakthrough therapy for anorexia nervosa, a condition with no FDA-approved medication. Rooted in the Israeli innovation ecosystem, Shortwave employs an IP-driven, capital-efficient strategy, utilizing strategic partnerships to optimize its drug discovery and development processes for eating disorders and other mental health indications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 08:00
Board/Management Information
Direction, Director Changes and Medical Adviser
English 20.9 KB
2025-08-19 13:50
Major Shareholding Notification
Holding(s) in Company
English 56.0 KB
2025-08-04 12:00
Board/Management Information
Clarification on Strategic Advisor Appointment
English 6.0 KB
2025-07-29 08:00
Share Issue/Capital Change
£250k Fundraising, New Directors & Review
English 27.3 KB
2025-06-24 14:10
Major Shareholding Notification
AQSE Only - Holding(s) in Company
English 56.2 KB
2025-06-16 11:21
Major Shareholding Notification
Holding(s) in Company
English 56.2 KB
2025-01-31 17:52
Earnings Release
Interim Results to 31 October 2024
English 115.6 KB
2024-12-23 13:00
Share Issue/Capital Change
Pre-Crowdfunding re Groundbreaking Treatment
English 9.5 KB
2024-11-29 16:16
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 7.2 KB
2024-11-27 15:12
Board/Management Information
Director Appointment and SPA Update
English 26.7 KB
2024-10-31 18:39
Annual Report
YEAR ENDED 30 APRIL 2024 AND DIRECTOR RESIGNATION
English 176.8 KB
2024-09-19 08:00
Regulatory News Service
Positive Pre-Clinical Result Drive to Human Trials
English 10.7 KB
2024-07-31 13:05
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 7.2 KB
2024-07-17 18:20
Major Shareholding Notification
TR1: Notification of Major Holdings
English 75.8 KB
2024-07-08 08:00
Share Issue/Capital Change
Company’s Patent Claims Confirmed
English 31.5 KB

Automate Your Workflow. Get a real-time feed of all Psych Capital Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Psych Capital Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan 2927
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX

Talk to a Data Expert

Have a question? We'll get back to you promptly.